Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KP-1508
- Development stage
- Preclinical
- Lead developer
- Kolon Pharma
01
Overview
KP-1508 is a proprietary investigational drug candidate being developed by Kolon Pharma, a subsidiary of the Kolon Group, for the treatment of idiopathic pulmonary fibrosis (IPF). Currently in the preclinical exploratory research phase, the drug represents part of the company's internal research and development efforts aimed at addressing fibrotic lung diseases. As of early 2024, Kolon Pharma has not publicly disclosed the specific molecular target, biological mechanism of action, or chemical modality for KP-1508. The program is part of a broader strategy by the Kolon Group to develop novel therapeutics for conditions with significant unmet medical needs.
Beyond the preview
Go deeper on KP-1508.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KP-1508.